The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson’s disease by Jęśko, Henryk et al.
©
 20
19
 b
y 
Ac
ta
 N
eu
ro
bi
ol
og
ia
e E
xp
er
im
en
ta
lis
The interplay between parkin and alpha‑synuclein; 
possible implications for the pathogenesis  
of Parkinson’s disease
Henryk Jęśko1†*, Anna M. Lenkiewicz2†, Anna Wilkaniec1 and Agata Adamczyk1 
1 Department of Cellular Signaling, M. Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland,  
2 Department of Regenerative Medicine, Preclinical Research Centre (CePT), Medical University of Warsaw, Warsaw, Poland,  
† Authors contributed equally to this work,  
* Email: hjesko@imdik.pan.pl
Parkin and alpha‑synuclein (α‑syn) are two key proteins involved in the pathophysiology of Parkinson’s disease (PD). Oligomerization/
aggregation and excessive secretion of α‑syn contributes to PD through free radical stress, mitochondrial impairment, and 
synaptic dysfunction. Parkin, an E3 ubiquitin ligase, is considered to be a  pleiotropic, neuroprotective protein that modulates 
metabolic turnover and the accumulation of α‑syn. This is in addition to parkin’s role in counteracting the more distant effects 
of α‑syn on cellular survival by altering proteasomal, autophagic, and calpain‑mediated protein degradation pathways that can 
reduce α‑syn levels. Moreover, parkin regulates mitochondrial turnover, cell survival, and immune phenomena – processes that 
are all known to be disturbed in PD. In addition, parkin might have an impact on the spreading and propagation of α‑syn by 
controlling its post‑translational modifications. On the other hand, recent research has shown that α‑syn oligomers affect the 
expression, post‑translational modification, and activity of parkin. This review focuses on the molecular mechanisms of cross‑talk 
between parkin and α‑syn in PD. The physical and functional interactions between α‑syn and parkin, which have been incompletely 
characterized to‑date, may present a new therapeutic avenue in PD and related synucleinopathies. The development of effective, 
clinically feasible modulators may offer great hopes for the therapy of PD. 
Key words: protein aggregation, cross‑talk, neurodegeneration, cell death 
INTRODUCTION 
Parkinson’s disease (PD) is one of the most com‑
mon age‑related neurodegenerative disorders. De‑
spite years of intense research and testing of candidate 
treatments, all available therapies are symptomatic. 
The long period of stealthy, relatively symptom‑free 
development is shared with other neurodegenerative 
disorders (notably, with Alzheimer’s disease – AD), 
and hampers diagnosis, elucidation of disease mecha‑
nisms, and possible therapy (reviewed in Jęśko et al., 
2017). The main neuropathological hallmarks of PD 
are 1) intraneuronal cytoplasmic inclusions, termed 
Lewy bodies (LB), that contain α‑synuclein (α‑syn) 
as a major component and multiple other proteins 
including the E3‑ubiquitin ligase parkin, and 2) the 
progressive degeneration of dopaminergic neurons in 
the substantia nigra pars compacta which leads to re‑
duced dopamine (DA) levels in the striatum – a brain 
region that controls locomotor activity. The major‑
ity of PD cases are characterized as spontaneous. 
Only about 20% of patients show a family history of 
the disease and, of those with a family history, only 
a minority follow Mendelian patterns of inheritance. 
α‑syn and parkin are two of the genes with mutations 
that have been associated with typical forms of PD 
(Coppedè, 2012). Beyond PD, other relatively common 
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synucleinopathies include the PD spectrum diseases 
PD dementia (PDD) and dementia with Lewy bodies 
(DLB), and the relatively more distant multiple sys‑
tem atrophy (MSA). 
α‑syn is a soluble, 140‑amino acid protein with pre‑
dominantly presynaptic localization, but is also found 
in lower quantities in other cell regions (e.g., nuclear 
envelope, perikaryon). α‑syn is abundantly expressed 
in the brain, particularly in the cerebral cortex, hip‑
pocampus, substantia nigra, striatum, and olfactory 
bulb, and is also present outside the central nervous 
system (CNS) (Adamczyk et al., 2005b; Taguchi et al., 
2016: Jęśko et al., 2017). The proposed physiological 
functions of α‑syn are numerous and complex. In‑
deed, α‑syn is implicated in synaptic signaling (i.e., 
neurotransmitter release, functioning of the synaptic 
vesicle pool), Ca2+ homeostasis, and the regulation of 
gene expression. Importantly, α‑syn plays a significant 
role in dopaminergic neurotransmission, which is se‑
lectively deregulated in PD. A wealth of data indicate 
that loss or perturbation of physiological activity of 
α‑syn contributes to the development and progres‑
sion of PD. However, results obtained to‑date focus 
primarily on α‑syn’s gain‑of‑function mechanism, i.e., 
the acquisition of neurotoxic properties by α‑syn. Mis‑
folded α‑syn oligomerizes and then forms fibrils, and 
is sometimes suggested to have prion‑like properties 
(the capability of initiating aggregation of further, ‘na‑
tive’ α‑syn molecules). Cell‑to‑cell transfer of α‑syn, 
whether leading to spread of misfolding or simply to 
α‑syn presence in recipient cells, is a novel mode of 
pathology propagation, previously underestimated 
but potentially crucial, leading to the characteristic 
spatial sequence of pathological events in PD develop‑
ment (Jęśko et al., 2017). The gain‑of‑function neuro‑
toxic alterations in α‑syn may be evoked by mutations 
in the α‑syn gene, SNCA, via post‑translational modi‑
fications of the α‑syn protein and/or by its oligomer‑
ization or aggregation. PD‑linked dominant SNCA mu‑
tations range from missense changes that cause single 
amino acid substitutions to gene dosage changes (i.e., 
duplication or triplication; Farrer et al., 1998, 2004). 
Deregulated post‑translational α‑syn modifications, 
including phosphorylation, oxidation, or nitration, 
may also alter the metabolism and function of α‑syn 
(Jęśko et al., 2017). Hypotheses describing potential 
mechanisms of α‑syn toxicity include (for review, see 
Wong and Krainc, 2017): 
• Disruption of numerous vesicular pathways, in‑
cluding deregulation of the DA release mechanism 
which may lead to intracellular accumulation and 
cytotoxic oxidation of the neurotransmitter. In ad‑
dition, disruption of autophagy, which governs the 
removal of dysfunctional proteins and organelles. 
• Damage to the endoplasmic reticulum (ER) and Gol‑
gi apparatus, leading to deregulated transport of 
macromolecules and induction of ER stress.
• Impaired mitochondrial fission and fusion.
• Deregulation of transcription factors. 
• Disrupted inter‑organellar contacts, such as mito‑
chondria‑associated ER membranes (MAM). 
Parkin is a 52kDa, 465aa E3 ubiquitin‑protein ligase 
with broad‑spectrum neuroprotective activities and is 
found in LB along with α‑syn. Parkin substrates include 
O‑glycosylated α‑syn, Aβ1‑42, and cytoskeletal proteins 
(reviewed in Shimura et al., 2012). Parkin is involved in 
the maintenance of mitochondrial metabolism, which 
is particularly critical in the richly arborized DAergic 
neurons of the substantia nigra (Giguère et al., 2018). As 
a component of the ubiquitin‑proteasome system (UPS), 
parkin plays a key role in the degradation of damaged 
or misfolded proteins, and in the removal of defective 
mitochondria via mitophagy (Geisler et al., 2010). Par‑
kin is engaged in 1) the classical K48‑G76 ubiquitina‑
tion which leads to proteasomal degradation, but also 
in 2) monoubiquitination and 3) K63‑linked polyubiq‑
uitination that targets proteins – or whole organelles 
– for autophagic degradation (Olzmann et al., 2007; 
Zheng and Hunter, 2013; Zhu et al., 2017). K63‑linked 
polyubiquitination additionally serves distinct signal‑
ing purposes in the regulation of protein synthesis‑de‑
pendent response to oxidative stress (Silva et al., 2015). 
Parkin can bind to promoter DNA and behave as 
a transcriptional activator or repressor, thereby regu‑
lating the gene expression of p53 or presenillin‑1 and 
‑2 (da Costa et al., 2009; Duplan et al., 2013). Moreover, 
parkin is translocated to the nucleus in response to 
DNA damage. In the nucleus, parkin binds to Nijmegen 
breakage syndrome 1 (NBS1), a protein engaged in DNA 
double strand break signaling and repair, and ensures 
its efficient recruitment to UV‑induced DNA lesions 
(Zhu et al., 2017). Parkin also monoubiquitinates prolif‑
erating cell nuclear antigen (PCNA), which is an essen‑
tial co‑factor for DNA polymerase δ that is engaged in 
repair‑linked and general DNA replication (Zhu et al., 
2017). Taken together, the resulting effects of parkin on 
DNA repair may underlie the observed increased risk of 
skin tumors in PD (Zhu et al., 2017). 
Various rearrangements of the parkin gene (PARK), 
including exon deletion, multiplication, and point mu‑
tations, have been implicated in the pathogenesis of 
familial PD (Pankratz et al., 2009). Analysis of the varia‑
tions of PARK as well as plasma levels of parkin protein 
may yield a useful diagnostic factor for PD (Geldenhuys 
et al., 2014). Indeed, disturbances in post‑translational 
modifications of parkin protein, such as phosphory‑
lation, S‑nitrosylation, or oxidative damage, might be 
linked to the development of PD (also in the sporadic 
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disease forms) (reviewed by Dawson and Dawson, 2014). 
Stimulation of parkin phosphorylation at Ser65 (by 
PINK1) has been shown to facilitate parkin recruitment 
to the mitochondria (Hertz et al., 2013). Thus, activa‑
tion of PINK1 with, for e.g., kinetin triphosphate, an 
ATP analog (Hertz et al., 2013), might promote parkin 
recruitment to the impaired mitochondria. 
THE POSSIBLE INVOLVEMENT OF PARKIN 
IN THE MODULATION OF Α‑SYNUCLEIN 
METABOLISM AND AGGREGATION 
Excessive α‑syn accumulation, oligomerization, and 
the resulting toxicity appear to be critical for the patho‑
genesis of PD and other synucleinopathies (Jęśko et al., 
2017). Indeed, oligomers, fibrils, and/or large aggre‑
gates of α‑syn form following overexpression of α‑syn, 
exposure to oxidative or nitrosative stress, apoptotic 
stimuli, or interactions with DA or histones (Gentile et 
al., 2008; Giasson et al., 2000; Goers et al.,2003; Mor et 
al., 2017; Ponzini et al., 2019; Singleton et al, 2004). 
Parkin and α‑syn secretion 
Recent studies indicate that α‑syn is secreted into 
the extracellular space, and secretion appears to be 
a precisely regulated, physiological process (Jęśko et 
al., 2017). However, in PD, abnormal excess release of 
monomeric and/or aggregated α‑syn might lead to free 
radical stress (Wilkaniec et al., 2019) and trigger immu‑
nological response of surrounding astrocytes and mi‑
croglia, thereby accelerating the neurotoxic insult (Al‑
len Reish and Standaert, 2015). Moreover, the internal‑
ization of secreted α‑syn by neurons and glia spreads 
the neurodegenerative pathology and involves other 
cell types, including cells that do not typically express 
significant levels of α‑syn (Jęśko et al., 2017). Trans‑
port of α‑syn to neighboring cells has been reported 
to propagate neurodegeneration (Desplats et al., 2009). 
α‑syn is sometimes likened to the prion protein due to 
its ability to transfer between different types of cells, 
and refold from the physiological α‑helix‑rich confor‑
mation into an oligomerization‑prone β‑sheet struc‑
ture, (Jęśko et al., 2017). 
The role of parkin in secretion of α‑syn into the extra‑
cellular space has not been studied extensively to‑date. 
Previous research demonstrates that normal function 
of parkin is essential for LB formation, given that mu‑
tations in the parkin gene result in the absence of LB 
(Chung et al., 2001). This has led to suggestion that the 
formation of intracellular inclusions might be a tissue 
protective mechanism reducing α‑syn release into ex‑
tracellular space and the propagation of the pathology 
to neighboring cells, effectively at the expense of single 
cell survival (Chung et al., 2001). Despite these data, it 
remains unclear whether parkin’s participation in inclu‑
sion formation is actually neuroprotective or not. 
Parkin and post‑translational modifications  
of α‑syn 
There is much evidence that the elusive physiolog‑
ical functions of α‑syn undergo tight regulation via 
covalent modifications. Moreover, many of these mod‑
ifications, such as Ser129 phosphorylation, nitration, 
mono‑/diubiquitination, and cleavage (e.g., C‑terminal 
proteolysis), have been shown to enhance α‑syn oligo‑
merization and may therefore influence α‑syn toxicity 
(Fig. 1). 
α‑syn is phosphorylated at serine residues Ser 87 
and Ser 129. Parkin overexpression leads to activation 
of protein phosphatase 2A (PP2A), which subsequently 
results in de‑phosphorylation of α‑syn at Ser 87 and Ser 
129. Dephosphorylation of α‑syn results in attenuation 
of α‑syn‑induced cell death and inflammation (Khan‑
delwal et al., 2010) (Fig. 1). 
Free radicals can cause oxidation of all four α‑syn 
methionine residues. Oxidation of methionine resi‑
Fig.  1. Parkin and α‑syn mutually regulate their post‑translational modi-
fications. Numerous cytotoxic actions of α‑syn require post‑translational 
modifications of its molecule, such as phosphorylation, nitration, or partial 
cleavage. Parkin‑dependent inhibition of monoamine oxidase (MAO) may 
decrease oxidation and nitration of α‑syn. Parkin, through increased pro-
tein phosphatase 2A (PP2A) activity and the resulting inhibition of polo‑like 
kinase 2 (PLK2), can also reduce α‑syn phosphorylation. In turn α‑Syn, 
through its influence on dopamine metabolism and signaling pathways 
can lead to decreased parkin E3 ubiquitin‑ligase activity.  
280 H. Jęśko et al. Acta Neurobiol Exp 2019, 79: 277–290
dues can subsequently promote the formation of α‑syn 
oligomers and inhibit α‑syn fibrillization, thus in‑
creasing α‑syn toxicity (Leong et al., 2009). Previous 
research has also documented tyrosine‑nitrated res‑
idues in α‑syn (Uversky et al., 2005). Although some 
results suggest that nitration of α‑syn has neuropro‑
tective effects (Yamin et al., 2003), other research 
shows that nitration results in decreased solubility 
of α‑syn, which subsequently impairs its proteolytic 
degradation and enhances formation of intracellular 
inclusions (Giasson et al., 2000). Moreover, nitration 
of α‑syn has been shown to increase toxicity towards 
DAergic neurons (Yu et al., 2010). Consistent with this, 
high levels of nitrated α‑syn have been found in LB 
from post‑mortem PD brains (Giasson et al., 2000). In 
addition, increased α‑syn nitration at Tyr39 can result 
from stress evoked by monoamine oxidase B (MAO‑B) 
(Danielson et al., 2009), whereas parkin can reduce 
MAO‑B expression (Jiang et al., 2006). Loss of parkin, in 
turn, led to increased MAO expression and free radical 
stress in human midbrain DAergic neurons (Jiang et al., 
2012) (Fig. 2A). 
Proteolytic cleavage of α‑syn may not only lead to 
its degradation, but also to its pathological aggrega‑
tion. Indeed, previous research shows that C‑termi‑
nally truncated α‑syn has a stronger tendency towards 
aggregation and is observed in pathologically altered 
neurites (intriguingly, also in AD without conventional 
LB) (Lewis et al., 2010). 
Importantly, post‑translational modifications of 
parkin may change its activity and role in the modu‑
lation of α‑syn metabolism (Fig. 1). Indeed, parkin un‑
dergoes an α‑syn‑induced S‑nitrosylation (Wilkaniec et 
al., 2019), which can lead to parkin autoubiquitination 
and degradation in PC12 cells (Wilkaniec et al., 2019). 
Other research has shown that covalent binding of DA 
reduces parkin solubility and inhibits its activity as an 
E3 ubiquitin ligase (LaVoie et al., 2005). Numerous ki‑
nases may be involved in the regulation of parkin phos‑
phorylation on serines 101, 127, 131, 378 and Tyr 143. 
One potential kinase is cdk 5, which regulates parkin 
solubility together with casein kinase‑1 (Chakraborty 
et al., 2017). Previous research in PC12 cells shows ac‑
tivation of cdk5 in response to α‑syn‑induced Ca2+ rise 
sensed by calpain. In addition, inhibition of cdk5 reduc‑
es α‑syn cytotoxicity (Czapski et al.,2013). It remains 
to be seen if parkin aggregation occurs in response to 
α‑syn‑evoked activation of cdk5 in vivo, and if the po‑
BA
Fig. 2. Parkin and α‑syn can aff ect dopamine neurotoxicity and selected pathways of programmed cell death signaling. (A) Both α‑syn and parkin aff ect 
dopaminergic neurotransmission, although especially parkin’s signifi cance is poorly characterized. Parkin can prevent cytosolic DA accumulation, partial‑
ly through inhibition of the complex infl uence of α‑syn on dopamine transport. Parkin may also reduce dopamine oxidation by inhibiting monoamine 
oxidase (MAO). (B) Parkin’s neuroprotective infl uence (largely exerted through PI3K/Akt signaling and through negative regulation of p53 expression) is 
disturbed in PD, underlying some of the neuronal susceptibility to death. In turn, α‑syn has a more ambiguous infl uence on p53, and – depending on 
concentration – can inhibit anti‑apoptotic Bcl‑2 family proteins. α‑syn accumulation may lead to the release of cytochrome c from mitochondria and acti‑
vation of caspases, and/or to the release of AIF which can signal parthanatos, a cell death mode engaging chromatin‑binding proteins normally associated 
with DNA repair. However, although links between parkin, α‑syn, and the AIF release/parthanatos have been observed, their exact mechanism is unclear. 
   stimulation of the expression or activity; 
   reduction of expression/inhibition of activity;
    ambiguous or changing interactions (positive or inhibitory infl uence depending on the concentration of the protein in question, cellular metabolic 
status, or biological model used).
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tential loss of parkin activity contributes to α‑syn neu‑
rotoxicity in the Parkinsonian brain. 
Parkin and α‑syn degradation 
The extensive network of redundant pathways that 
are capable of degrading α‑syn highlights the impor‑
tance of continuous control of α‑syn concentration. 
Strikingly, parkin has been found to modulate the deg‑
radation of α‑syn by multiple mechanisms. 
α‑syn is a substrate for parkin‑mediated ubiquiti‑
nation, and the UPS appears to be a major pathway of 
α‑syn degradation (Jęśko et al., 2017). Whereas loss of 
parkin activity leads to accumulation of non‑ubiquiti‑
nated forms of α‑syn (Shimura et al., 2001), compounds 
that augment proteasomal α‑syn degradation have 
beneficial neuroprotective effects and are considered 
to have a potential therapeutic application in PD (Jęśko 
et al., 2017; Li et al., 2018). However, accumulation and 
aggregation of α‑syn can negatively affect UPS func‑
tion, potentially leading to a runaway failure (Snyder 
et al., 2003). The mechanism and significance of α‑syn 
level control by UPS still raise questions. For example, 
not all α‑syn cleaved by proteasomes is ubiquitinated. 
In addition, the aforementioned incomplete cleavage 
of α‑syn by a pathologically overloaded proteasome 
system may lead to the generation of α‑syn fragments 
that are prone to aggregation (Liu et al., 2005). 
α‑syn is also degraded via the autophagic pathway. 
Indeed, PD‑linked alterations in parkin lead to the ac‑
cumulation of unprocessed α‑syn in autophagosomes 
(Lonskaya et al., 2013). Similar to UPS, the potential of 
autophagy as a backup degradation pathway for α‑syn 
is limited by its sensitivity to inhibition by accumulat‑
ed or aggregated α‑syn (Jęśko et al., 2017). 
Parkin‑activated cysteine protease calpain is also 
involved in degradation of α‑syn (Kim et al., 2003). 
However, the ability of this cleavage mechanism to lim‑
it neurotoxic α‑syn accumulation and/or aggregation 
is unclear (Beyer and Ariza, 2013). 
THE ROLE OF PARKIN IN  
THE MODULATION OF PATHWAYS 
MEDIATING Α‑SYNUCLEIN TOXICITY 
Parkin’s protective role against α‑syn toxicity 
might involve multiple mechanisms besides direct in‑
teractions. Parkin can modify α‑syn’s influence on the 
DAergic system, potentially affecting the DA‑mediated 
toxicity in PD; parkin also has a plethora of neuropro‑
tective activities that might counteract more distant 
effects of α‑syn‑related pathology (Table I). 
Parkin and the α‑syn – affected dopamine 
metabolism, transport, and secretion 
α‑syn has been shown to affect various aspects of 
DAergic signaling (Fig. 2A), including DA biosynthesis, 
release, and re‑uptake. Parkin has also been shown to 
affect multiple α‑syn‑modulated steps of DA metab‑
olism and transport, although the results are some‑
what contradictory. For example, research shows that 
α‑syn binds to and inhibits tyrosine hydroxylase (TH), 
the rate‑limiting DA biosynthesis enzyme (Perez et 
al., 2002). In pathological conditions, α‑syn alters DA 
synaptic homeostasis, including dopamine transporter 
(DAT) modification (Adamczyk et al., 2006, Moszczyns‑
ka et al., 2007) and impairment of DA packaging into 
synaptic vesicles, which leads to cytosolic DA accu‑
mulation, DA oxidation, and cellular stress (Guo et al., 
2008). Parkin appears to have an opposite influence on 
DA, as disruption of parkin function leads to cytosolic 
DA accumulation at the cost of packaging into vesicles 
(Itier et al., 2003). The role of parkin in DAT regulation 
is less characterized, although it is known that parkin 
can bind to DAT and prevent DAT’s interaction with 
α‑syn (Moszczynska et al., 2007). Consistent with this, 
reduced DAT levels have been detected in parkin‑defi‑
cient mice (Itier et al., 2003) (see Fig. 2A and Table I). 
Parkin and the α‑syn‑induced oxidative and 
nitrosative stress 
Although α‑syn has been widely associated with the 
induction of oxidative stress, some results suggest that 
its physiological role might instead be linked to anti‑
oxidative defense (Deas et al., 2016; Jęśko et al., 2017). 
Interestingly, aggregation of α‑syn appears to gener‑
ate and be driven by free radicals. Indeed, previous re‑
search shows that hydroxyl radical (•OH) is produced in 
the course of in vitro α‑syn aggregation in the presence 
of iron (II) (Turnbull et al., 2001), and that iron‑induced 
α‑syn aggregation can be blocked by the reactive oxy‑
gen species (ROS) scavenger vitamin E (Li et al., 2011). 
Reactive nitrogen species (RNS) and nitrosative stress 
have also been shown to contribute to Parkinsonian pa‑
thology (Gatto et al., 2000). Indeed, extracellular α‑syn 
can open N‑methyl‑D‑aspartate receptor (NMDAR) ion 
channels, which leads to Ca2+ influx and activation of 
neuronal nitric oxide synthase (nNOS) in the rat brain 
(Adamczyk et al., 2009). Nitric oxide (NO) can react with 
superoxide to form the highly harmful peroxynitrite 
(ONOO‑), which damages proteins, lipids, and DNA. α‑syn 
also contributes to the oxidative imbalance by depleting 
cellular glutathione levels and can also induce aggrega‑
tion of superoxide dismutase protein. However, results 
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Table I. Mechanisms of α‑syn neurotoxicity and their modulation by parkin.
Parkin References α‑Syn References
Neurotransmission 
↑ dopamine packaging into 
synaptic vesicles (VMAT) Itier et al., 2003 
↓ tyrosine hydroxylase 
activity Perez et al., 2002
↑ dopamine transporter 
level Itier et al., 2003 [?] dopamine re‑uptake 
Adamczyk et al., 2006; 
Moszczynska et al., 2007; 
↓ dopamine transporter 
interaction with α‑syn Moszczynska et al., 2007 
↓ vesicular monoamine 
transporter‑2 activity Guo et al., 2008
Oxidative / nitrosative  
and ER stress 
↑ free radical generation 
during aggregation process
Turnbull et al., 2001 
Li et al., 2011
↓ oxidative stress 
↓ MAO‑A, MAO‑B 
expression and activity 
Itier et al., 2003 
Jiang et al., 2006 
Palacino et al., 2004 
↑ NMDA 
receptor‑dependent nitric 
oxide synthesis 
Adamczyk et al., 2009 
↑ expression of inducible 
nitric oxide synthase in 
microglia 
Su et al., 2008 
↓ ER stress signaling 
(Pael‑R) Imai et al., 2001 ↑ ER stress Xu et al., 2014 
↑ autophagic turnover of 
damaged macromolecules 
and organelles 
Lonskaya et al., 2013 
↓ proteasomal and 
autophagic protein 
degradation (especially 
mutated α‑syn) 
reviewed in Jęśko  
et al., 2017 
Cytoskeleton,  
cellular transport 
↓ α‑syn – dependent 
(hyper)phosphorylation 
of microtubule associated 
proteins by GSK‑3β, JNK, 
ERK, and p38 
Khandelwal et al., 2010; 
McLelland et al., 2018; 
Moussa, 2009;  
Ren et al., 2009 
↑ GSK‑3β activity, 
cytoskeleton 
destabilizagtion 
Duka et al., 2009 
Gąssowska et al., 2014 
Khandelwal et al., 2010 
↓ cellular transport of 
organellae (overexpressed 
or mutant α‑syn) 
Xie and Chung, 2012
Mitochondria 
[?] mitochondrial fusion 
and fission depending 
on stress levels 
↓ α‑syn – induced 
mitochondrial 
fragmentation 
Kamp et al., 2010 
↑ mitochondrial fission,  
↓ mitochondrial fusion  
and elongation 
Kamp et al., 2010 
Norris et al., 2015 
↑ neuronal respiration 
↑ transcription of 
mitochondrial genes 
Damiano et al., 2014 
Palacino et al., 2004 
Kuroda et al., 2006 
Shin et al., 2011 
↓ activity of transcription 
factors engaged in the 
expression of genes 
coding for mitochondrial 
proteins 
Ryan et al., 2013 
↑ mitophagy, targeting 
damaged mitochondria  
for elimination 
Ashrafi and Schwarz, 2015 
Chan and Chan, 2011 
Jin and Youle, 2013 
Norris et al., 2015 
[?] mitophagy 
(overexpressed, mutant,  
or aggregated α‑syn) 
Choubey et al., 2011 
Grassi et al., 2018 
Martinez et al., 2018 
Shaltouki et al., 2018 
Cell death 
↓ cell death via apoptosis 
and autophagy 
↓ parthanatos? 
Hwang et al., 2017;  
Lee et al., 2013;  
Lonskaya et al., 2013; 
Vercammen et al., 2006
↑ apoptosis 
↑ autophagic cell death? 
↑ parthanatos 
Adamczyk et al., 2010 
Desplats et al., 2009; 
Gómez‑Santos et al., 2003; 
Kam et al., 2018;  
Venderova, Park 2012
Inflammation 
↓ α‑syn – dependent 
microglia activation Khandelwal et al., 2010
↑ production of 
pro‑inflammatory 
cytokines in microglia 
Khandelwal et al., 2010;  
Su et al., 2008
↓ nigral sensitivity to 
inflammation‑related 
degeneration 
Frank‑Cannon et al., 2008 
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on these effects are inconsistent (Deas et al., 2016; Koo 
et al., 2013; Koch et al., 2016). Moreover, oxidized gluta‑
thione produced in the course of ROS detoxication can 
itself contribute to α‑syn aggregation (Paik et al., 2003). 
In turn, oxidative or nitrosative stress may influence in‑
tracellular α‑syn localization, function, and release into 
the extracellular space (Jang et al., 2010; Sangchot et al., 
2002). Oxidative or nitrosative stress may also mediate 
cytotoxic outcomes of DA metabolism deregulation by 
α‑syn (Riobó et al., 2002). 
It has been suggested that parkin plays a neuropro‑
tective role against oxidative stress. Indeed, parkin‑null 
mice have been shown to display increased vulnerabili‑
ty to oxidative stress (Palacino et al., 2004),  and parkin 
can suppress the expression and activity of MAO‑A and 
‑B, which generate ROS during DA oxidation (Itier et al., 
2003; Jiang et al., 2006) (see Fig. 2A and Table I). Howev‑
er, parkin protein itself has been shown to be extremely 
sensitive to biochemical stressors. Indeed, oxidative con‑
ditions and DA toxicity can inhibit parkin, and induce its 
assembly into multimers that may be degraded via mac‑
roautophagy or the roteasome (Wang et al., 2005). 
Parkin, α‑syn, endoplasmic reticulum (ER) stress, 
and the unfolded protein response 
Parkin and α‑syn have also been shown to have 
roughly opposite functions in the mechanism of ER 
stress and the unfolded protein response (see Table I). 
Whereas α‑syn is considered to be necessary for ER 
stress‑induced signaling via 78, 94‑kDa glucose‑regu‑
lated protein (GRP78/94), C/EBP homologous protein 
(CHOP), and caspase‑12 (Xu et al., 2014), parkin pro‑
tects the cells against the unfolded protein‑induced 
cell death by promoting degradation of parkin asso‑
ciated endothelin‑like receptor (Pael‑R) (Imai et al., 
2001). Moreover, parkin has been shown to suppress 
degeneration of DA neurons induced by Pael‑R toxicity 
(Yang et al., 2003).
The protective role of parkin against 
α‑syn‑evoked microtubule destabilization 
Microtubules are involved in the axonal transport 
of proteins and organelles. Microtubule disruption has 
been shown to inhibit neuronal activity, and may also 
lead to axonal accumulation of cargo normally trans‑
ported along the cytoskeleton, such as aggregated pro‑
teins (thereby boosting α‑syn aggregation) or damaged 
mitochondria‑containing autophagosomes (thus fur‑
ther deepening auto‑ or mitophagic dysfunction and 
mitochondrial deregulation) (Esteves et al., 2014). 
Mitochondrial abnormalities observed in PD may 
lead to a lack of energy, which detrimentally affects the 
functioning of the microtubular cytoskeleton, for e.g., 
the molecular motors that transport the cargo (Esteves 
et al., 2014). 
The role of α‑syn in microtubule depolymerization 
and polymerization in nigral DAergic neurons has been 
studied by several groups. These studies have shown 
that α‑syn binds to and is necessary for the activity of 
glycogen synthase kinase 3β (GSK‑3β), a serine/thre‑
onine kinase that phosphorylates microtubule‑associ‑
ated protein (MAP) Tau (Duka et al., 2009; Khandelwal et 
al., 2010). α‑syn‑dependent Tau hyperphosphorylation 
by GSK‑3β results in destabilization of the cytoskeleton 
and impairment of cellular survival (Duka et al., 2009; 
Khandelwal et al., 2010; Gąssowska et al., 2014). 
Research on a mutation in the parkin gene that re‑
sults in Tau hyperphosphorylation suggests that func‑
tional parkin deficits can trigger Tau pathology (Sán‑
chez et al., 2002). Indeed, parkin can decrease GSK‑3β 
protein levels and attenuate the α‑syn‑evoked GSK‑3β 
activation, Tau hyperphosphorylation, inflammation, 
and cell death (Moussa, 2009; Khandelwal et al., 2010) 
(see Table I). Parkin might also play a neuroprotective 
role by attenuating the activation of the MAP kinases 
c‑Jun N‑terminal kinase (JNK), extracellular signal‑re‑
lated kinase (ERK), and p38 (Ren et al., 2009). Moreover, 
parkin has been shown to have a stabilizing effect on 
microtubules (Ren et al., 2009). 
Potential anti‑inflammatory role of parkin 
Inflammation has been shown to play an import‑
ant role in the progression of PD. Indeed, α‑syn has 
been shown to act as an inflammatory stimulator that 
modulates microglial expression of proinflammato‑
ry cytokines, such as tumor necrosis factor α (TNF‑α) 
and inducible NOS (iNOS) (Khandelwal et al., 2010; Su 
et al., 2008). Nitrosative and oxidative stress has been 
observed in cells overexpressing or treated with α‑syn 
(Wilkaniec et al., 2019). α‑syn may exert its effects in 
part through the NF‑κB pathway, which is crucially en‑
gaged in inflammatory signaling (Yuan et al., 2008). 
It has been suggested that parkin plays a protective 
role against inflammatory responses evoked by α‑syn 
(Table I). Indeed, research shows enhanced inflamma‑
tory damage in parkin knock‑out mice (Frank‑Cannon 
et al., 2008), whereas virally expressed parkin signifi‑
cantly reversed the effect of α‑syn on glial number and 
morphology, and reduced the up‑regulation of TNF‑α 
and iNOS (Khandelwal et al., 2010). It has been pro‑
posed that the neuroprotective effects of parkin de‑
pend on the NF‑κB pathway (Henn et al., 2007). Howev‑
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er, α‑syn‑induced stress can lead to S‑nitrosylation and 
degradation of parkin (Wilkaniec et al., 2019). 
Parkin and α‑syn in the regulation of apoptosis, 
autophagy, and parthanatos 
Neuronal death in PD involves elevated apoptotic 
effectors, including caspase‑1, ‑3, ‑8, and ‑9 (Hartmann 
et al., 2000; 2001; Mogi et al., 2000). α‑syn has been 
shown to trigger down‑regulation of the anti‑apoptotic 
protein Bcl‑2, which leads to cytochrome c release and 
apoptotic cell death via caspases 3 and 9 (Adamczyk 
et al.,2010; Yuan et al., 2008; Liu et al., 2011) (Fig. 2B). 
α‑syn also has complex impact on the expression and 
activity of p53 (Martin et al., 2006; da Costa et al., 2009). 
However, in some circumstances, α‑syn might protect 
against cell death, for e.g., through the aforementioned 
prevention of DA accumulation and oxidation following 
parkin knockdown (Machida et al., 2005). 
The role of both α‑syn and parkin on the PI3K‑Akt/
PKB pathway has been incompletely characterized 
to‑date. The PI3K‑Akt/PKB pathway is a highly inter‑
connected modulator of cellular metabolism and sur‑
vival and death through, for e.g., NF‑κB, GSK‑3β, Fork‑
head family transcription factors, Bad, or caspase‑9. 
Parkin supports pro‑survival PI3K‑Akt signaling (Fallon 
et al., 2006) whereas α‑syn has a more complex role. 
Nanomolar α‑syn activates PI3K‑Akt whereas micromo‑
lar α‑syn has been shown to exert opposite effects, in‑
cluding reduction of Bcl‑xL expression, up‑regulation 
of Bax, and inducing the release of cytochrome c from 
mitochondria (Seo et al., 2002). Based on these data, 
it is highly probable that the fine‑tuned activities of 
α‑syn in this context may be successfully modified by 
the documented interactions with parkin.
Autophagy as a cell death mechanism also appears 
to be involved in PD (Venderova and Park, 2012). In‑
deed, α‑syn has been shown to be involved in autopha‑
gosome regulation by negatively affecting early stages 
of autophagosome formation. These data suggest that 
a loss‑of‑function mechanism might be involved in PD 
pathogenesis (Winslow and Rubinsztein, 2011). 
Parthanatos is a relatively recently character‑
ized mode of cell death that was named after PAR, 
poly(ADP‑ribose) and Thanatos. Parthanatos involves 
proteins that are typically engaged in DNA repair, in‑
cluding poly(ADP‑ribose) polymerase (PARP1) or 8‑oxoG 
glycosylase1 (OGG1), These proteins lead to PAR‑medi‑
ated signaling from the nucleus to the mitochondria, 
triggering release of apoptosis‑inducing factor (AIF), 
chromatin condensation and large scale fragmentation, 
and ultimately, cell death. Parthanatos seems to be sig‑
nificantly involved in PD and MPTP‑induced models of 
PD (Lee et al., 2014). α‑syn is known to interact with AIF 
signaling (Zhu et al., 2011) and has been shown to in‑
teract bi‑directionally with PARP‑1 signaling, although 
the topic requires further research (Adamczyk et al., 
2005a; Adamczyk and Kaźmierczak, 2009; Chiba‑Falek 
et al., 2005; Outeiro et al., 2007). 
Several reports indicate that parkin protects against 
autophagic and apoptotic cell death in DA neurons 
(Hwang et al., 2017; Vercammen et al., 2006). In addition, 
loss of parkin due to decreased solubility in PD or genet‑
ic ablation in animal models leads to increased suscep‑
tibility of neurons to apoptosis (Vercammen et al., 2006; 
Lonskaya et al., 2013) (see Table I). However, parkin has 
also been shown to support neuroprotective autophagy 
of proteins and damaged organelles (Khan et al., 2017; 
Lonskaya et al., 2013). This neuroprotective has been 
shown to involve parkin’s physical interaction with the 
p53 promoter, which leads to down‑regulation of p53 
mRNA and p53‑dependent signaling. PD‑linked par‑
kin mutations abolish this interaction (da Costa et al., 
2009). Parkin may also exert its anti‑apoptotic functions 
through the aforementioned regulation of pro‑survival 
Akt signaling (Fallon et al., 2006; Hasegawa et al., 2008). 
Defining roles of parkin and α‑syn in 
mitochondrial remodeling and dynamics 
To uphold the pool of bioenergetically competent 
mitochondria, the ‘life cycle’ of mitochondria must 
pass through the stages of biogenesis, remodeling via 
repeated cycles of fusion/fission, and mitophagy (see 
Fig. 3). Although the mechanistic details of the neu‑
roprotective mechanism behind fusion/fission remain 
obscure, it has been hypothesized that fission could im‑
prove mitochondrial quality through asymmetric seg‑
regation of faulty proteins into one daughter organelle. 
Fusion, in contrast might allow for complementation of 
the best components from the two original mitochon‑
dria (Scarffe et al., 2014). 
Overexpression of wildtype (wt) or mutant α‑syn 
has been shown to promote neuronal cell death via 
mitochondrial dysfunction and fragmentation (Kamp 
et al., 2010; Zhu et al., 2011). α‑syn is an inhibitor of 
membrane fusion and knockdown of α‑syn has been 
shown to promote mitochondrial elongation (Norris 
et al., 2015). Interestingly, mitochondrial fragmenta‑
tion evoked by α‑syn overexpression can be rescued 
by co‑expression of parkin, PINK1, or DJ‑1, suggesting 
that α‑syn and parkin may take part in the same path‑
way (as described below) (Kamp et al., 2010). Recently, 
it was also indicated that α‑syn accumulation or the 
α‑syn A53T mutation leads to inhibition of mitochon‑
drial motility (Xie and Chung, 2012). 
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Parkin also appears to be an essential component of 
the quality control s ystem in the mitochondria (Vend‑
erova and Park, 2012), and inactivation of parkin leads 
to reduced striatal neuron respiration and oxidative 
d amage (Damiano et al., 2014; Palacino et al., 2004). 
Parkin has been shown to regulate multiple aspects of 
the mitochondrial life cycle, from biogenesis to mito‑
 phagy (Lim et al., 2012) (see also Table I). These regula‑
tory effects are described below: 
• Parkin enhances transcription of mitochondri‑
al DNA (mtDNA) via its negative influence on the 
transcription modulator, parkin interacting sub‑
strate (PARIS). Loss of parkin activity in PD leads 
to the accumulation of PARIS and inhibition of its 
target peroxisome, proliferator‑activated recep‑
tor gamma‑coactivator 1α (PGC1‑α) (Kuroda et al., 
2006; Shin et al., 2011). Down‑regulation of PGC1‑α 
has been shown to increase risk of PD (Zheng et al., 
2010) whereas parkin appears to prevent against the 
drop of PGC1‑α level, thus augmenting mitochon‑
drial biosynthesis. α‑syn can also signal through 
PGC1‑α; indeed, α‑syn has been shown to reduce 
mitochondrial biogenesis through increased tran‑
scription factor oxidation and S‑nitrosylation (Ryan 
et al., 2013). Preservation of PGC‑1α levels through 
maintenance of parkin activity or reduction of PAR‑
IS neurotoxicity have been proposed as therapeutic 
strategies in PD (Dawson and Dawson, 2014). 
• Parkin regulates mitochondrial fusion, fission, 
and mitophagy in a manner that depends on cel‑
lular condition. In physiological conditions, parkin 
can inhibit fusion‑promoting Mfn family proteins 
and the fission‑related Drp1. Under moderate mi‑
tochondrial stress, parkin may play a fusion‑pro‑
moting role that allows the repair of damaged 
organelles while counteracting fission. Of note, 
fission occurs intensely in parkin‑deficient cells 
in response to mitochondrial toxins (Norris et al., 
2015). In contrast, heavily damaged mitochondria 
trigger its mitophagy‑promoting ac tivity (Norris et 
al., 2015). 
• Parkin may also play an essential role in intracellu‑
lar transport of mitochondria through regulation of 
proteins of the axonal and dendritic trafficking ma‑
chinery, including Miro1 (McLelland et al., 2018). 
Impaired clearance of damaged mitochondria may 
be one of the triggers causing demise of DAergic neu‑
rons in PD brain. Post‑mitotic neurons have fewer op‑
portunities to remove defective mitochondria than cy‑
cling cells, and at the same time, post‑mitotic neurons 
have extreme energy demands, making them more vul‑
nerable to disturbances. Previous studies confirm ac‑
cumulation of defective mitochondria PD pat ients (de 
Vries and Przedborski, 2013). 
Mitophagy is a subtype of lysosome‑mediated auto‑
phagy that is required to clear damaged mitochondria. 
Research shows that many genes linked to PD are en‑
gaged in the regulation of mito phagy (Ryan et al., 2015). 
Disturbed or delayed mitophagy in the presence of ac‑
cumulated α‑syn may be an essential mediator of α‑syn 
toxicity and thus represent a pathological mechanism 
leading to PD (Shaltouki et al.,2018). Other research 
demonstrates enhanced mitophagy in a cell line that 
overexpresses α‑syn (Martinez et al., 2018); in particu‑
lar, in midbrain DAergic neurons transfected with A53T 
α‑syn (which, in that case, leads to cell  death) (Choubey 
et al., 2011). Mitophagy was also found to be stimulated 
by nonfibrillar, phosphorylated α‑syn aggregates found 
in the neurons of PD patient brains (Grassi et al.,2018). 
The role of α‑syn in autophagy of mitochondria is 
therefore unclear, and its disease‑associated molecular 
alterations appear to autophagy profoundly. 
Interestingly, under exposure to the mitochondri‑
al toxin, parkin, together with E2 conjugating enzyme 
Ubc13 has been shown to stimulate K63‑linked α‑syn 
Fig.  3. Involvement of parkin and α‑syn in the mitochondrial  ‘life cycle’. 
Mitochondrial ‘life cycle’ involves their biogenesis, remodeling through re‑
peated rounds of fusion/fi ssion, and mitophagy. It is suggested that parkin 
causes ubiquitination and degradation of the PARIS protein, removing its 
negative infl uence on the levels of PGC‑1α; thus, parkin leads to elevated 
PGC‑1α, increased replication of mtDNA, and intensifi ed mitochondrial 
biogenesis. Moreover, depending on the state of cellular metabolism par‑
kin may upregulate mitochondrial motility and mitophagy through inter‑
action with Miro‑1 and autophagolysosomal proteins, respectively. α‑syn – 
evoked oxidative/nitrosative stress downregulates de novo mitochondrial 
biogenesis. α‑syn also supports mitochondrial fi ssion, inhibits fusion, and 
can infl uence mitophagy leading to accumulation of damaged mitochon‑
dria and cell death. 
   stimulation of the expression or activity;
   reduction of expression/inhibition of activity; 
   ambiguous or changing infl uence.
286 H. Jęśko et al. Acta Neurobiol Exp 2019, 79: 277–290
ubiquitination. The observed effect of parkin on mito‑
chondrial turnover can be phenocopied by α‑syn‑tar‑
geting siRNA (Norris et al., 2015). Parkin itself has been 
shown to play an essential role in removing damaged 
mitochondria from the cell via mitophagy, including 
local liquidation of mitochondria in the axon, which 
has direct relevance for neuronal activity (Ashrafi and 
Schwarz, 2015; Chan and Chan, 2011). Mitochondria 
that accumulate misfolded proteins in the matrix can 
trigger the translocation of parkin, which activates 
subsequent removal (Jin and Youle, 2013) (Fig. 3). 
THE RECIPROCAL INFLUENCE OF 
Α‑SYN ON PARKIN, AND Α‑SYN‑PARKIN 
CO‑REGULATION 
α‑syn appears to modify parkin’s ubiquitination 
activity and function by binding to parkin and shifts 
parkin’s activity towards K63‑linked ubiquitination. 
α‑syn’s modification of parkin stimulates mitochon‑
drial fusion, and this interaction occurs in response to 
mild mitochondrial stress (Norris et al., 2015). α‑syn can 
also modify the phosphorylation state of parkin, given 
that overexpression of A53T α‑syn has been shown to 
leads to parkin modification by p38MAPK. Modification 
of parkin, in turn, reduces its cytoprotective influence 
on mitochondrial turnover (Chen et al., 2018). 
 A recent study by Liu et al. (2019) described another 
mechanism linking deregulation of parkin with α‑syn 
in PD. In this work, Liu et al. (2019) found an upregu‑
lation of ubiquitin‑specific protease USP13 in Parkin‑
sonian brains. USP13 removes ubiquitin from proteins, 
and thus, USP13 is able to reduce α‑syn‑induced par‑
kin ubiquitination. Likewise, USP13 de‑ubiquitinated 
α‑syn, and a USP13 knockdown has been shown to facil‑
itate the ubiquitination and removal of α‑syn. However, 
the observed effect on α‑syn ubiquitination was shown 
to be independent of parkin (Liu et al., 2019). 
CONCLUSIONS 
Parkin is extensively engaged in protein degrada‑
tion pathways, and as such may offer significant thera‑
peutic potential. α‑syn levels may be controlled by par‑
kin‑dependent proteasomal degradation. Parkin also 
appears to modulate autophagic degradation of α‑syn, 
as well as, control calpain, an α‑syn‑degrading enzyme. 
All of these pathways are shown to be disturbed in PD, 
at least partially due to parkin’s sensitivity to α‑syn‑in‑
duced stress. In‑depth understanding of this mecha‑
nism is a necessary aspect of PD characterization and 
may lead to identification of new therapeutic oppor‑
tunities. Parkin and α‑syn mutually regulate their own 
post‑translational modifications. This relatively easy 
to manipulate mechanism influences the neuropro‑
tective activity of parkin and the tendency of α‑syn to 
aggregate, thus offering important insights into patho‑
physiological mechanisms leading to PD and potential 
therapeutic value. Importantly, α‑syn also alters parkin 
levels and activity (Wilkaniec et al., 2019), potentially 
creating a cycle of self‑fueling pathology. 
The multiple neuroprotective functions of parkin 
raise hopes that, in addition to modulating α‑syn be‑
havior, parkin may also alter the downstream effects of 
α‑syn neurotoxicity. Effects on α‑syn neurotoxicity may 
allow for a more established and/or easier to implement 
avenue for therapeutic intervention. A promising aspect 
of parkin’s role in the cell is linked to its engagement 
in mitochondrial turnover and/or quality maintenance, 
and in cytoskeletal functions. These functions are partic‑
ularly important in neuronal cells, which are extremely 
dependent on efficient oxidative metabolism, and effi‑
cient maintenance of intracellular transport. In line with 
this, mitochondrial metabolism is known to be compro‑
mised in neurodegenerative disorders. Moreover, parkin 
may influence multiple steps of DA turnover, prevent‑
ing its intracellular accumulation, oxidation‑mediated 
toxicity, and moderating other mechanisms of cellular 
stress. Parkin can also modulate cell survival signaling 
and inhibit apoptotic and autophagic cell death, and 
parthanatos. Neuronal death is a relatively distant effect 
of the partially obscure processes that lead to the devel‑
opment of PD. However, as only symptomatic treatments 
are currently available for neurodegenerative disorders, 
interventions that are capable of preserving neuronal 
populations in affected brain regions would be of ex‑
treme value in the struggle against PD. 
Recent progress in the understanding of parkin and 
α‑syn dysfunction provide hope for the discovery of 
new therapeutic approaches for synucleinopathies. Re‑
search addressing practical aspects of the restoration 
of parkin activity primarily concentrate on: 
• Compounds that stimulate parkin activity and/or 
its recruitment to impaired mitochondria or small 
molecules that mimic phospho‑ubiquitin action 
or mimic the effects of PINK1‑dependent parkin 
phosphorylation (Kazlauskaite et al., 2014). Hydro‑
gen sulfide donors may be another therapeutic ap‑
proach, as sulfhydration enhances parkin E3 ligase 
activity (Vandiver et al., 2013). 
• Anti‑oxidative compounds such as creatine, coen‑
zyme Q10, resveratrol, and uric acid have been tested 
in PD (Chaturvedi and Beal, 2013; Ferretta et al., 2014; 
Jin et al., 2014), given that oxidative and nitrosative 
stress has been shown to decrease parkin solubility, 
thus impairing its function (Wang et al., 2005). 
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